Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

4.21
Delayed Data
As of May 26
 +0.06 / +1.45%
Today’s Change
3.15
Today|||52-Week Range
10.06
+1.94%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$575.6M

Company Description

Achillion Pharmaceuticals, Inc. engages in the research and development of small molecule drug therapies for infectious diseases and immune system disorders. It intends to commercialize its anti-viral medicines for the treatment of hepatitis C and resistant bacterial infections. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Contact Information

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven Connecticut 06511
P:(203) 624-7000
Investor Relations:

Employees

Shareholders

Other institutional45.68%
Individual stakeholders38.12%
Mutual fund holders27.47%

Top Executives

Milind S. DeshpandePresident, Chief Executive Officer & Director
Mary Kay FentonCFO, Principal Accounting Officer & Executive VP
David ApelianChief Medical Officer & Executive Vice President
Joel C. BarrishChief Scientific Officer & Executive VP
Joseph TruittChief Commercial Officer & Executive VP